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Marañón, 28007 Madrid, Spain
Correspondence should be addressed to Begoña Quintana-Villamandos; begoquinti@gmail.com
Received 29 September 2018; Revised 15 April 2019; Accepted 16 June 2019
Academic Editor: Oliver von Bohlen und Halbach
Copyright © 2019 Begoña Quintana-Villamandos et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Dronedarone is recommended for the treatment of atrial fibrillation. However, we do not know its effect on vascular remodeling.
This study was designed to assess whether dronedarone has the potential to improve the intramyocardial artery remodeling
induced by chronic hypertension. Ten-month-old male spontaneously hypertensive rats (SHR) were randomly assigned to receive
dronedarone (100mg/kg) or vehicle. Age-matchedmaleWistar-Kyoto rats served as controls. After 14 days of treatment, we studied
the structure (geometry and fibrosis) of the intramyocardial artery using histological analysis. Nitric oxide (NO) in plasma was
analyzed. In the untreated SHR, we observed a significant increase in external diameter, lumen diameter, wall width, cross-sectional
area, and collagen volume density, as was expected in the experimental model. Dronedarone induced a significant decrease in wall
width, cross-sectional area, and collagen volume density in SHR-D in comparison with untreated SHR. The values obtained in
SHR-D were similar in the WKY control group. We found significantly higher NO levels in plasma in SHR-D than in untreated




Hypertension leads to adverse remodeling (structural alter-
ations) in the coronary artery wall and therefore increases the
incidence of cardiovascular events [1, 2]. Antihypertensive
therapy reverses vascular structural alterations and reduces
cardiovascular morbidity [3, 4]. Therefore, the benefits by
improving structural alterations in the coronary artery in
patients with hypertension are an important factor in the
selection of antihypertensive therapy [5].
Dronedarone is a novel antiarrhythmic drug for atrial fib-
rillation, acting as a multichannel blocker [6]. Dronedarone
reduced the incidence of hospitalization due to cardiovascu-
lar events or death in patients with atrial fibrillation [7, 8];
however it is avoided in patients with unstable chronic heart
failure [9]. In a preclinical study, we previously analyzed
early regression of left ventricular hypertrophy following
short-term use of antiarrhythmic agents and we found that
dronedarone produces regression of left ventricular hyper-
trophy after two weeks of treatment [10]. However, its effect
on intramyocardial artery remodeling has not been analyzed
to date. Left ventricular hypertrophy, which is the usual
complication of hypertension, is associated with structural
changes, namely, coronary remodeling [11]; therefore we
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tested the hypothesis that short-term administration (two
weeks) of dronedarone could improve the intramyocardial
artery remodeling.
This study was designed to evaluate the efficacy of
dronedarone in attenuating the intramyocardial branch of the
obtuse marginal artery remodeling in spontaneously hyper-
tensive rats (SHR), the most widely used animal models for
human essential hypertension, left ventricular hypertrophy,
and coronary damage.
2. Methods
2.1. Ethics. The study was performed in accordance with
European Union Guidelines to use experimental animals
(Directive 2010/63/EU and Spanish Law RD 53/2013) and
was approved by the Ethics Committee of Hospital Gregorio
Marañón, Madrid, Spain.
2.2. Animals and Experimental Protocols. Ten-month-
old male SHR were randomly assigned to receive oral
dronedarone (100mg/kg once daily) (SHR-D, n=11) for a
period of 14 days or to receive vehicle (SHR, n=11). A third
group of normotensive control rats (WKY, n=11) was also
added. Once the treatment was finished, the rats were killed
by decapitation after sedation with diazepam 4mg/kg and
ketamine 10mg/kg (intraperitoneal injection).
2.3. In Vivo Measurements (Arterial Pressure and Heart
Rate). As described in detail in previous studies [12] systolic
arterial pressure (SAP) and heart rate (HR) were measured
using the plethysmographic method on the tail artery of
conscious animals (Niprem 546, Cibertec, Madrid, Spain).
Several determinationsweremade before and after treatment,
and the findings were considered valid if 10 consecutive
measurements were within 10mmHg of each other.
2.4. Intramyocardial Artery Structure. We analyzed 6 animals
for each group as described in detail previously [12–14].
Hearts were excised and fixed in 4% paraformaldehyde. An
equatorial cross section of the left ventricle was embedded in
paraffin. Sections (3 sections/rat) were cut (thickness, 5𝜇m)
and stained with orcein [12]. The intramyocardial branch
of the obtuse marginal artery (branch of the circumflex
coronary artery) of the left ventricle was located, and the
external diameter (ED) (lumen diameter + tunica intima +
tunica media + tunica adventitia) and lumen diameter (LD)
of the intramyocardial artery were measured as described
[12]. Wall width (WW) was calculated as (ED−LD)/2, the
wall-to-lumen ratio (W/L) as (WW/LD)×100, and the media
cross-sectional area (CSA) (tunica intima + tunica media
+ tunica adventitia) as (𝜋/4)×(ED2−LD2) [13]. For collagen
staining, 5𝜇msections (3 sections/rat) of paraffin blockswere
stained with picrosirius red, and the collagen volume density
(CD) was determined using a stereological method [14].
2.5. Measurement of Plasma Nitrite Level. We analyzed 5
animals from each group. The same protocols described in
previous studies [15] were followed in the present one. Plasma
nitrite level was assessed using a Griess reaction-based pro-
tocol adapted from other authors [16, 17]. To eliminate thiols
that interfere with the Griess reaction, 100 𝜇L of plasma or
nitrite standard was mixed with 10 𝜇L of N-ethylenediamine.
The protein from samples was precipitated by addition of 110
𝜇L of trichloroacetic acid. 50 𝜇L of supernatant (obtained by
centrifugation) was mixed with 50 𝜇L of saturated vanadium
chloride, 25 𝜇L of sulfanilamide, and 25 𝜇L of N-naphthyl-
ethylenediamine. The mixture was incubated at 37∘C for 1
hour, and absorbance was read at 540 nm.
2.6. Statistical Analysis. The results were expressed asmedian
and 25th and 75th percentiles and analyzed with the Mann-
Whitney U test (arterial structure parameters and nitrites).
The results were expressed as mean ± SEM and analyzed
using repeated-measures analysis of variance (physiological
parameters). Statistical significance was set at P ≤ 0.05.
The analysis was performed using IBM SPSS Statistics for
Windows, version 20.0.
3. Results
3.1. Administration of Dronedarone Lowers Blood Pressure and
Heart Rate. Rat weight was significantly higher inWKY than
in SHR and SHR-D (460.40±1.12 vs. 401.22±3.02 g, P<0.01,
and 460.40±1.12 vs. 380.51±6.21 g, P<0.001, respectively);
however, the difference was not statistically different between
SHR and SHR-D. 2
Dronedarone significantly reduced SAP and HR in SHR-
D with respect to control SHR. SAP remained unchanged in
SHR-D and WKY (Table 1).
3.2. Administration of Dronedarone Improves Structural
Intramyocardial Artery Remodeling. The effect of
dronedarone on artery morphology is shown in Table 2 and
Figure 1. SHR presented hypertrophic outward remodeling
associated with a significant increase in CSA and LD in the
intramyocardial branch of the obtuse marginal artery when
compared withWKY. CSA andWWwere significantly lower
after 2 weeks of treatment with dronedarone in SHR-D than
in SHR, and no differences were observed with respect to
WKY. LD in SHR-D did not differ from that in SHR. ED
was significantly increased in SHR when compared with
WKY; however, administration of dronedarone significantly
decreased this parameter in SHR-D when compared with
SHR.
The effect of dronedarone on intramyocardial artery
fibrosis is shown in Table 2 and Figure 2. Vascular collagen
was expressed as CD. Compared with WKY rats, the CD
of the intramyocardial artery was significantly increased in
SHR. Dronedarone significantly reduced the collagen fiber
content, and the CD value was comparable to that of WKY.
3.3. Administration of Dronedarone Increases the Bioavailabil-
ity of Nitric Oxide (NO). Compared with WKY rats, the NO
of the intramyocardial artery was significantly decreased in
SHR. Dronedarone significantly increased the NO, and this
parameter was comparable to that of WKY (Table 2).
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Table 1: Systolic blood pressure and heart rate fromWKY, SHR, and SHR-D.
Groups Time treatment (days) SBP (mmHg) HR (bpm)
WKY (n=6) 0 130 ± 21 414 ± 20
14 137 ± 23 401 ± 24
SHR (n=6) 0 174 ± 15∗∗ 395 ± 21
14 180 ± 11∗∗ 410 ± 18
SHR-D (n=6) 0 176 ± 21∗∗ 398 ± 12
14 141 ± 12## 301 ± 17∗∗∗,###
SBP, systolic blood pressure; HR, heart rate. Values are shown as mean ± SEM. Statistically significant differences are shown (∗∗P < 0.01 versus WKY; ∗∗∗P <
0.001 versus WKY; ##P < 0.01 versus SHR; ###P < 0.001 versus SHR).
Table 2: Geometry and collagen in the intramyocardial artery fromWKY, SHR, and SHR-D.
Structural parameters WKY SHR SHR-D
ED (𝜇m) 151 (150-219) 349 (312-377)∗∗ 250 (248-303)∗∗,#
LD (𝜇m) 68 (60-129) 201 (110-212)∗ 176 (144-226)∗
WW (𝜇m) 43 (36-47) 82 (71-107)∗∗ 49 (38-52)##
W/L (%) 60 (37-74) 46 (33-80) 27 (18-36)∗,#
CSA (𝜇m2) 15058 (14381-21195) 70227 (54016-82310)∗∗ 31885 (25215-38623)##
CD (%) 13.83 (11.81-21.40) 41.66 (40.68-52.78)∗∗ 15.38 (12.57-17.25)##
NO (𝜇M) 1.76 (1.68-1.84) 1.35 (1.32-1.40)∗ 1.66 (1.46-1.80)#
ED, external diameter; LD, lumen diameter; WW, wall width;W/L, wall/lumen ratio; CSA, cross-sectional area; CD, collagen volume density; NO, nitric oxide.
Data are expressed as median (25th-75th percentiles). Statistically significant differences are shown ( ∗P<0.05 versus WKY; ∗∗P<0.01 versus WKY; #P<0.05
versus SHR; ##P<0.01 versus SHR). Geometry and collagen (n=6) and NO (n=5).
4. Discussion
Our results show that two weeks of treatment with
dronedarone improves the intramyocardial artery
remodeling in adult SHR through increased nitric oxide
bioavailability.
In the literature, we find that antihypertensive and antiar-
rhythmic drugs produce regression coronary artery remodel-
ing after chronic treatment in SHR: administration of losar-
tan for 5 weeks reduced wall thickness and CSA, amlodipine
and enalapril led to a reduction in media thickness and CSA
after 12 weeks, perindopril and indapamide led to a reduction
in CSA and vessel diameter after 8 weeks, and lisinopril
reduced the thickness of the coronary artery media after 12
weeks [18–21]. Furthermore, short-term administration of
esmolol (48 hours) reduced wall thickness, CSA, and vessel
diameter [15, 22]. However, the effect of dronedarone on
vascular remodeling has not been investigated to date.
Functional and structural alterations of the coronary
circulation have been well documented in left ventricular
hypertrophy [1]. In a preclinical study, we show that short-
term treatment (two weeks) with dronedarone has the poten-
tial to reverse the left ventricular hypertrophy induced by
arterial hypertension in the SHR model of compensated
ventricular hypertrophy [10]. In this context, we found it of
interest to assess the impact of dronedarone in attenuating
intramyocardial artery remodeling. And it is plausible that
dronedarone induces changes in intramyocardial remodel-
ing.
Dronedarone is a new drug (class III antiarrhythmic)
used for the maintenance of sinus rhythm and control of
ventricular rate [23]. Dronedarone produces a multichannel
blockade of the sodium, potassium, and calcium channels
and exhibits antiadrenergic properties [6]. Dronedarone
reduces heart rate and blood pressure, and it has a direct
cardioprotective effect (reduction in infarct size in an ani-
mal model of ischemia/reperfusion).Therefore, dronedarone
reduces the risk of acute coronary syndrome [24]. This
cardioprotective effect could be related to the improvement
of structural alterations in intramyocardial arteries observed
in the present study.
In the present study, the mechanism underlying
dronedarone improving the intramyocardial artery
remodeling could be related in part to an increase in
the bioavailability of NO. Coronary artery remodeling in
the presence of hypertension implies structural changes
[25], but also endothelial dysfunction [26, 27]. Dronedarone
acts on the coronary artery producing vasodilatation by
activating the nitric oxide synthase pathway [28]. NO
inhibits smooth muscle cell (SMC) proliferation of the
arterial wall [29], decreasing wall thickness. Therefore, NO
is a key regulator of cardiovascular remodeling thanks to
its antihypertrophic and direct antiproliferative effects [30].
Our group has demonstrated that another antihypertensive
drug (esmolol) reverses structural alterations in the coronary
arteries (decreased media thickness and SMC count) by
increasing the bioavailability of NO in SHR [15, 22]. With
the data available from the literature, the mechanisms
discussed above remain speculative and future studies are
required to gain insight into the mechanism underlying
dronedarone-induced protective effects on intramyocardial
arteries remodeling.
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WKY SHR SHR-D
Figure 1: Histological sections of the intramyocardial branch of the obtuse marginal artery from WKY, SHR, and SHR-D (orcein, 100x,
100𝜇m).
WKY SHR SHR-D
Figure 2: Images of collagen staining (picrosirius red, 40x, 200 𝜇m) of the intramyocardial branch of the obtuse marginal artery fromWKY,
SHR, and SHR-D. CA, coronary artery; SE, subepicardium.
Our results provide preclinical data on the beneficial
effects of dronedarone on intramyocardial artery remodeling,
which is associated with an increased incidence of cardio-
vascular events [1, 2]. During the last decade, dronedarone
has been studied extensively in a wide range of experimen-
tal and clinical settings. These studies have revelated that
dronedarone is an interesting antiarrhythmic agent for the
treatment of atrial fibrillation [31]. Dronedarone reduces
cardiovascular morbidity and mortality in clinically stable
patients with other risk factors for recurrent atrial fibrillation
[23]. Atrial fibrillation is the most common arrhythmia in
clinical practice with significant morbidity and mortality [6].
In fact, atrial fibrillation induces ischemic microcirculatory
flow abnormalities in the ventricle contributing to the risk
of acute coronary syndromes [32]. Therefore, dronedarone
is now widely used to treat patients with atrial fibrillation.
However, regression of structural alterations in the intramy-
ocardial arteries in patients with atrial fibrillation could play
a key role in the selection of antiarrhythmic therapy. Further
studies are needed to clarify the underlying mechanisms of
positive effect of dronedarone on vascular remodeling.
The present study is subject to limitations.This study was
designed to evaluate the efficacy of dronedarone in attenuat-
ing the intramyocardial branch of the obtuse marginal artery
remodeling in SHR. Our results show that dronedarone
improves structural intramyocardial artery remodeling; how-
ever, vascular remodeling in the presence of hypertension
implies not only alterations in the structure of vessels, but
also endothelial dysfunction [26, 27]. Thus, a major goal of
research could be to analyze the effect of dronedarone on
coronary artery vasodilator function. On the other hand, the
complicated mechanisms underlying vascular remodeling
involve not only decreased NO bioavailability. In fact, activa-
tion of the pathways of vascular smooth muscle contraction,
vascular oxidative stress, and inflammation are implicated
[27]. Therefore, we need to explore new mechanisms related
to the positive effect of dronedarone on vascular remodeling.
In conclusion, this study suggests that dronedarone
improves the intramyocardial artery remodeling induced by
chronic hypertension in SHR through increased nitric oxide
bioavailability.
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request. 3
Disclosure
Preliminary results of this study were presented in the 45th
Physiological Society of Thailand Annual Meeting 2017:
“Translational Physiology: Implications in Health and Dis-
ease.”
Conflicts of Interest
The authors declare that they have no conflicts of interest
regarding the publication of this paper.
BioMed Research International 5
Acknowledgments
This study was supported by Fondo de Investigaciones Sani-
tarias (PI13/01261, PI16/02069) and Fondos Feder.
References
[1] P. G. Camici, I. Olivotto, and O. E. Rimoldi, “The coronary
circulation and blood flow in left ventricular hypertrophy,”
Journal of Molecular and Cellular Cardiology, vol. 52, no. 4, pp.
857–864, 2012.
[2] H. D. Intengan and E. L. Schiffrin, “Vascular remodeling in
hypertension: roles of apoptosis, inflammation, and fibrosis,”
Hypertension, vol. 38, no. 3, part 2, pp. 581–587, 2001.
[3] A. Rehman and E. L. Schiffrin, “Vascular effects of antihyper-
tensive drug therapy,” Current Hypertension Reports, vol. 12, no.
4, pp. 226–232, 2010.
[4] E. L. Schiffrin, “Vascular remodeling and endothelial function
in hypertensive patients: effects of antihypertensive therapy,”
Scandinavian Cardiovascular Journal, Supplement, vol. 32, no.
47, pp. 15–21, 1998.
[5] E. Agabiti-Rosei, “Structural and functional changes of the
microcirculation in hypertension: influence of pharmacological
therapy,” Drugs, vol. 63, no. 1, pp. 19–29, 2003.
[6] R. Tadros, S. Nattel, and J. G. Andrade, “Dronedarone: basic
pharmacology and clinical use,” Cardiac Electrophysiology Clin-
ics, vol. 8, no. 2, pp. 453–465, 2016.
[7] M. Cohen and C. Boiangiu, “The management of patients with
atrial fibrillation and dronedarone’s place in therapy,” Advances
in Therapy, vol. 28, no. 12, pp. 1059–1077, 2011.
[8] S. H. Hohnloser, H. J. G.M. Crijns, M. V. Eickels et al., “Effect of
dronedarone on cardiovascular events in atrial fibrillation,”The
New England Journal of Medicine, vol. 360, no. 7, pp. 668–678,
2009.
[9] E. J. Lee and J. Kim, “Evaluation of dronedarone as a therapeutic
option for patients with atrial fibrillation,” Journal of Clinical
Pharmacy andTherapeutics, vol. 39, no. 2, pp. 112–117, 2014.
[10] B. Quintana-Villamandos, J. J. G. D. Diego, M. J. Delgado-
Martos et al., “Dronedarone produces early regression of
myocardial remodelling in structural heart disease,” PLoS ONE,
vol. 12, no. 11, Article ID e0188442, 2017.
[11] E. Escobar, “Hypertension and coronary heart disease,” Journal
of Human Hypertension, vol. 16, no. S1, pp. S61–S63, 2002.
[12] B. Quintana-Villamandos, M. J. Delgado-Martos, and E.
Delgado-Baeza, “Adverse remodeling of the obtuse marginal
artery in compensatory hypertrophiedmyocardium from spon-
taneously hypertensive rats,” Cardiovascular Pathology, vol. 26,
pp. 51–54, 2017.
[13] H. Yokoyama, D. B. Averill, K. B. Brosnihan, R. D. Smith, E. L.
Schiffrin, and C. M. Ferrario, “Role of blood pressure reduction
in prevention of cardiac and vascular hypertrophy,” American
Journal of Hypertension, vol. 18, no. 7, pp. 922–929, 2005.
[14] H. J. G. Gundersen, T. F. Bendtsen, L. Korbo et al., “Some
new, simple and efficient stereological methods and their use in
pathological research and diagnosis,” APMIS-Acta Pathologica,
Microbiologica et Immunologica Scandinavica, vol. 96, no. 5, pp.
379–394, 1988.
[15] A. Arnalich-Montiel, M. C. González, E. Delgado-Baeza et
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